The Nausea drugs in development market research report provides comprehensive information on the therapeutics under development for Nausea , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nausea . Buy the report here.

Smarter leaders trust GlobalData


Data Insights Nausea - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nausea and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Nausea by eight companies/universities/institutes. The top development phase for Nausea is preclinical with four drugs in that stage. The Nausea pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Nausea pipeline products market are: Charleston Laboratories, Daewoo Pharmaceutical and Medipure Pharmaceuticals.

The key targets in the Nausea pipeline products market include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), and Histamine H1 Receptor (HRH1).

The key mechanisms of action in the Nausea pipeline product include Histamine H1 Receptor (HRH1) Antagonist with three drugs in Phase III. The Nausea pipeline products include eight routes of administration with the top ROA being Sublingual and one key molecule types in the Nausea pipeline products market including Small Molecule.

Nausea overview

Nausea is considered as a protective mechanism or as a warning to the organism to avoid potential toxic ingestion. It can also be defined as unpleasant painless feeling that one will imminently vomit. It often coexists with vomiting.

For a complete picture of Nausea ‘s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.